Get the Stockscreener App
1.97
8.84%
0.16
Gain Therapeutics Inc stock is traded at $1.97, with a volume of 467.18K.
It is up +8.84% in the last 24 hours and up +21.60% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.81
Open:
$1.81
24h Volume:
467.18K
Relative Volume:
1.59
Market Cap:
$70.82M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.7909
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
+13.87%
1M Performance:
+21.60%
6M Performance:
-13.22%
1Y Performance:
+50.38%
1-Day Range:
$1.81
$1.98
1-Week Range:
$1.65
$1.98
52-Week Range:
$0.95
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.97 | 63.63M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Fed Impact & Precise Buy Zone Tips - Newser
Visual trend scoring systems applied to Gain Therapeutics Inc.July 2025 Action & Long-Term Growth Stock Strategies - Newser
Is Gain Therapeutics Inc. showing signs of accumulationJuly 2025 Trade Ideas & Daily Stock Momentum Reports - Newser
Key resistance and support levels for Gain Therapeutics Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
Chart overlay techniques for tracking Gain Therapeutics Inc.Trade Performance Summary & Precise Buy Zone Tips - Newser
Best data tools to analyze Gain Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - Newser
Chart based exit strategy for Gain Therapeutics Inc.2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
What the charts say about Gain Therapeutics Inc. todayEarnings Beat & Technical Entry and Exit Alerts - Newser
Real time alert setup for Gain Therapeutics Inc. performanceWeekly Loss Report & Verified Momentum Stock Ideas - Newser
Is This a Bottoming Phase for Gain Therapeutics Inc.Market Risk Analysis & Weekly Market Pulse Alerts - classian.co.kr
Is Gain Therapeutics Inc. forming a reversal patternBond Market & Short-Term Trading Opportunity Alerts - Newser
Short interest data insights for Gain Therapeutics Inc.July 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Gain Therapeutics shares rise 5.20% intraday after BioXcel Therapeutics announces positive FDA Pre-sNDA. - AInvest
Gain Therapeutics Stock Soars 10.4% on Innovation Push - AInvest
Will Gain Therapeutics Inc. benefit from seasonality2025 Volatility Report & Free Real-Time Volume Trigger Notifications - 선데이타임즈
Why Gain Therapeutics Inc. stock attracts strong analyst attentionQuarterly Trade Report & Comprehensive Market Scan Insights - Newser
Candlestick signals on Gain Therapeutics Inc. stock todayWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - Newser
Has Gain Therapeutics Inc. found a price floorQuarterly Profit Summary & Weekly High Conviction Ideas - Newser
Chartists See Breakout Potential in Gain Therapeutics Inc.Quarterly Profit Summary & Weekly Chart Analysis and Trade Guides - beatles.ru
Chart Analysts Warn of Resistance Near Gain Therapeutics Inc. PriceJuly 2025 EndofMonth & Stock Portfolio Risk Control - metal.it
Using data models to predict Gain Therapeutics Inc. stock movementM&A Rumor & AI Enhanced Market Trend Forecasts - Newser
Published on: 2025-08-16 10:33:24 - sundaytimes.kr
Short Term Trend Reversal in Gain Therapeutics Inc. Possible2025 Trading Volume Trends & Smart Money Movement Alerts - beatles.ru
Using flow based indicators on Gain Therapeutics Inc.July 2025 Summary & Scalable Portfolio Growth Methods - Newser
Buy Recommendation for Gain Therapeutics Based on Parkinson's Drug Development and Strong Financial Position - AInvest
Gain Therapeutics (NASDAQ:GANX) Given New $6.00 Price Target at Roth Capital - Defense World
Gain Therapeutics, Inc. shares rise 3.27% intraday after Perspective Therapeutics presented positive [212Pb]VMT-α-NET study update at ASCO Annual Meeting. - AInvest
Intraday Charts Show Spike in Gain Therapeutics Inc. ActivityBond Market & Smart Swing Trading Alerts - sundaytimes.kr
What analysts say about Gain Therapeutics Inc. stock outlookMarket Activity Report & Daily Profit Focused Screening - Newser
What analysts say about Gain Therapeutics Inc. stock outlook [2025 Market Sentiment]High Accuracy Investment Signals - Newser
Gain Therapeutics Inc.’s Price Action Aligns with Quant SignalsReal-Time Analysis With Entry Targets In Progress - 선데이타임즈
Gain Therapeutics completes Q2 2025 with Phase 1b enrolment, $7.1mln in net proceeds. - AInvest
Gain Therapeutics Reports Financial Results for Second Quarter 2025 - TradingView
Gain Therapeutics, Inc. shares rise 4.11% intraday after Aardvark Therapeutics reports positive ARD-201 preclinical results. - AInvest
Gain Therapeutics reports Q2 EPS (19c), consensus (17c) - TipRanks
Gain Therapeutics Fast-Tracks Parkinson's Drug Trial: Key Results Coming Q4 2025, Raises $7.1M - Stock Titan
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):